Kandy Therapeutics competitive analysis

Explore Kandy Therapeutics's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 9, 2025
Patent NumberGrant DateTitleTotal Oppositions
Nov 22, 2023Novel Pharmaceutical Formulation Comprising Dual Nk-1/Nk-3 Receptor Antagonists1
Aug 23, 2023An Nk-1/Nk-3 Receptor Antagonist For The Treatment Of Sex-Hormone-Dependent Diseases1

Latest publications and patents of Kandy Therapeutics New

Explore the latest publications and patents granted to Kandy Therapeutics, showcasing their recent innovations and technological advancements.

Last updated on: Oct 8, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Kandy Therapeutics

Nov 22, 2023Novel Pharmaceutical Formulation Comprising Dual Nk-1/Nk-3 Receptor AntagonistsGranted And Under Opposition
Aug 23, 2023An Nk-1/Nk-3 Receptor Antagonist For The Treatment Of Sex-Hormone-Dependent DiseasesRevoked

Latest PTAB cases involving Kandy Therapeutics

Discover the latest PTAB cases involving Kandy Therapeutics, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Kandy Therapeutics with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 9, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
KANDY THERAPEUTICS - 2 - -
AERA27 - - -